Portola Announces Pricing of Public Offering of Common Stock
04 Décembre 2015 - 2:00PM
Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced today the
pricing of its underwritten public offering of 3,125,000 shares of
its common stock at a price to the public of $48.00 per
share. In addition, the underwriters of the offering have
been granted a 30-day option to purchase up to an additional
468,750 shares from Portola at the public offering price. The
offering is expected to close on December 9, 2015, subject to
customary closing conditions.
Morgan Stanley, Credit Suisse and Citigroup are acting as joint
book-running managers and Cowen and Company is acting as a
co-manager for the offering. A preliminary prospectus supplement
and final prospectus supplement may be obtained from the offices of
Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180
Varick Street, 2nd Floor, New York, NY 10014, or Credit Suisse
Securities (USA) LLC, Attention: Prospectus Department, One Madison
Avenue, New York, NY 10010, by email at
newyork.prospectus@credit-suisse.com or by toll-free call to (800)
221-1037.
A registration statement relating to these securities has been
filed with the Securities and Exchange Commission and became
effective on November 9, 2015. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company
developing product candidates that could significantly advance the
fields of thrombosis and other hematologic diseases. The Company is
advancing its three wholly-owned programs using novel biomarker and
genetic approaches that may increase the likelihood of clinical,
regulatory and commercial success of its potentially life-saving
therapies. Portola's partnered program is focused on developing
selective Syk inhibitors for inflammatory conditions.
Forward-Looking Statements
This announcement contains forward-looking statements, including
statements relating to Portola Pharmaceuticals’ expectations
regarding the completion, timing and size of the proposed public
offering. These statements are subject to significant risks and
uncertainties and actual results could differ materially from those
projected. Portola Pharmaceuticals cautions investors not to place
undue reliance on the forward-looking statements contained in this
release. These risks and uncertainties include, without limitation,
risks and uncertainties related to market conditions and
satisfaction of customary closing conditions related to the public
offering. There can be no assurance that Portola Pharmaceuticals
will be able to complete the public offering on the anticipated
terms, or at all. Risks and uncertainties relating to Portola
Pharmaceuticals and its business can be found in the “Risk Factors”
section of Portola Pharmaceuticals’ Quarterly Report on Form 10-Q
for the third quarter of 2015, which was filed on November 9, 2015,
and in the prospectus supplement related to the proposed offering
filed with the SEC. Portola Pharmaceuticals undertakes no duty or
obligation to update any forward-looking statements contained in
this release as a result of new information, future events or
changes in Portola Pharmaceuticals’ expectations.
Investor Contact:
Ana Kapor
Portola Pharmaceuticals
ir@portola.com
Media Contact:
Julie Normart
W2O Group
jnormart@w2ogroup.com
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024